Tom Price Confirmed, Humana Exit, Cancer Moonshot, and Cooling Caps
In this week’s BioBlog we look at the confirmation of Tom Price, the exit of Humana in the exchanges, new developments in the Cancer Moonshot initiative, and the use of cooling caps during chemotherapy.
ASCO is looking forward to working with Price to help shape the future of cancer research and the quality of cancer care.
Humana has announced that it plans on exiting the ObamaCare exchanges in 2018, creating concerns that other companies may soon follow and leave people with few or no options for insurance.
With the transition to the Trump Administration, there is speculation if the Cancer Moonshot initiative will survive, but given the strong bipartisan support it is believed that it has the momentum to keep going.
Fred Hutch Lab Will Lead Biden Cancer Moonshot Project, Aimed at More Effectively Matching Patients to Treatments
The Fred Hutch lab has been selected to lead the development of protein tests than could be used to better match patients to specific treatments.
In two recent studies researchers have found that cooling caps used during breast cancer chemotherapy can reduce the chance of hair loss when used before, during, and after treatment.